Rudman D, Feller A G, Cohn L, Shetty K R, Rudman I W, Draper M W
Department of Medicine, Medical College of Wisconsin, Milwaukee.
Horm Res. 1991;36 Suppl 1:73-81. doi: 10.1159/000182193.
Body composition changes progressively in mid and late adulthood. Lean body mass in men over 50 years old contracts at an average rate of -0.6% per year. Body weight tends to remain stable because of a reciprocal expansion of adipose mass. The shrinkage of the lean body mass reflects the atrophy of skeletal muscles, skin and visceral organs. Because growth hormone causes expansion of the lean body mass and contraction of the adipose mass, and because growth hormone secretion tends to diminish in late adulthood, it has been postulated that geriatric hyposomatotropism is a contributory cause to the body composition changes described above. The authors have tested this hypothesis by recruiting 45 independent men over 61 years old with plasma somatomedin C level below 0.35 U/ml, indicating little or no detectable growth hormone secretion. The 21-month protocol was as follows: baseline period 0-6 months, experimental period 6-18 months and post-experimental period 18-21 months. During the experimental period, 26 men (group I) received approximately 0.03 mg/kg of biosynthetic human growth hormone (hGH) subcutaneously 3 times a week, while 19 men (group II) received no treatment. Plasma somatomedin C was measured monthly. The following outcome variables were measured at 0, 6, 12 and 18 months: lean body mass, adipose mass, skin thickness (dermis plus epidermis), sizes of the liver, spleen and kidneys, the cross sectional areas of ten muscle groups, and bone density at 9 skeletal sites. Lean body mass and adipose mass were also measured at 21 months. In group I, hGH treatment raised the plasma somatomedin C level and maintained it in the range 0.5-1.5 U/ml.(ABSTRACT TRUNCATED AT 250 WORDS)
成年中期和后期身体成分会逐渐发生变化。50岁以上男性的瘦体重平均每年以-0.6%的速度减少。由于脂肪量的相应增加,体重往往保持稳定。瘦体重的减少反映了骨骼肌、皮肤和内脏器官的萎缩。因为生长激素会使瘦体重增加、脂肪量减少,且成年后期生长激素分泌往往会减少,所以有人推测老年期生长激素分泌不足是上述身体成分变化的一个促成因素。作者通过招募45名61岁以上、血浆生长调节素C水平低于0.35 U/ml(表明几乎检测不到生长激素分泌或没有生长激素分泌)的独立男性来验证这一假设。21个月的实验方案如下:基线期0 - 6个月,实验期6 - 18个月,实验后期18 - 21个月。在实验期,26名男性(第一组)每周皮下注射约0.03 mg/kg的生物合成人生长激素(hGH)3次,而19名男性(第二组)不接受治疗。每月测量血浆生长调节素C。在0、6、12和18个月时测量以下结果变量:瘦体重、脂肪量、皮肤厚度(真皮加表皮)、肝脏、脾脏和肾脏的大小、十个肌肉群的横截面积以及9个骨骼部位的骨密度。在21个月时也测量了瘦体重和脂肪量。在第一组中,hGH治疗提高了血浆生长调节素C水平并将其维持在0.5 - 1.5 U/ml的范围内。(摘要截短于250字)